BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

...help treat colon and other cancers harboring loss-of-function HACE1 mutations. In a mouse model of HACE1-mutant...
...and RIPK3. Next steps include testing inhibition of TNFRSF1A or RIPK3 in models of other HACE1-mutant...
...kinase 3 (RIPK3; RIP3 ); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1 ; CD120a ); HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 (HACE1)...
Items per page:
1 - 1 of 1